Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has reported Invested Capital for 9 consecutive years, with $789.2 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital rose 390.51% year-over-year to $789.2 million; the trailing twelve-month figure through Dec 2025 stood at $789.2 million (up 390.51% YoY), and the FY2025 full-year result was $789.2 million, up 390.51% from the prior year.
• Invested Capital grew to $789.2 million in Q4 2025 per ALNY's latest filing, from $355.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $1.3 billion in Q2 2021 and bottomed at -$158.2 million in Q4 2022.
• Historically, Invested Capital has averaged $763.1 million across 4 years, with a median of $821.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Invested Capital sank 112.52% in 2022, then jumped 390.51% in 2025.
• Over 4 years, Invested Capital stood at $1.3 billion in 2021, then tumbled by 112.52% to -$158.2 million in 2022, then surged by 201.68% to $160.9 million in 2024, then surged by 390.51% to $789.2 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $789.2 million, $355.2 million, and $676.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.